期刊文献+

骨化三醇联合盐酸司维拉姆对慢性肾功能衰竭患者血清甲状旁腺激素的影响 被引量:27

原文传递
导出
摘要 目的探讨骨化三醇(罗盖全)联合盐酸司维拉姆对慢性肾功能衰竭(CRF)患者血清全段甲状旁腺激素(iPTH)浓度的影响。方法将32例iPTH在33~55pmol/L的维持性血液透析患者随机分为3组,3组均口服钙尔奇D(Cal-trateD)900mg/d。Ⅰ组,口服小剂量罗盖全;Ⅱ组,小剂量罗盖全与盐酸司维拉姆联合使用;Ⅲ组,大剂量罗盖全冲击治疗。结果治疗8周后Ⅱ组患者血清磷(P)、iPTH、碱性磷酸酶(ALP)、低密度脂蛋白胆固醇(LDL-C)较治疗前降低,差异有统计学意义(P<0.05);高密度脂蛋白胆固醇(HDL-C)、胆固醇(TC)、甘油三酯(TG)没有显著性变化,差异无统计学意义(P>0.05)。Ⅲ组患者治疗后血ALP及iPTH较治疗前下降,差异有统计学意义(P<0.05)。Ⅱ组、Ⅲ组患者治疗后较Ⅰ组患者血P、iPTH下降,Ⅱ组患者的LDL-C较Ⅰ组明显下降,差异有统计学意义(P<0.05)。Ⅱ组与Ⅲ组治疗8周后iPTH、ALP均有所下降,但两组差异无统计学意义(P>0.05);Ⅱ组患者血P、LDL-C明显下降,与Ⅲ组相比差异有统计学意义(P<0.05)。结论血清iPTH在33~55pmol/L的维持性血液透析患者中,小剂量罗盖全与盐酸司维拉姆联合使用与大剂量罗盖全冲击治疗均可以使血清iPTH浓度下降,但两种治疗方式对iPTH的影响没有明显区别。
出处 《中华临床医师杂志(电子版)》 CAS 2011年第2期137-138,共2页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献8

  • 1Dellegrottaglie S,Sanz J,Rajagopalan S.Vascular calcification in patients with chronic kidney disease.Blood Purif,2006,24(1):56-62.
  • 2Giachelli CM.Vascular calcification mechanisms.J Am Soc Nephrol,2004,15(12):2959-2964.
  • 3Raggi P,Bellasi A,Ferramosea E,et al.Association of pulse wave velocity with vaseular and vascular calcificationin hemodialysis patients.Kidney Int,2007,71(8):802-807.
  • 4Albaaj F,Hutchison AJ.Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.Expert Opin Pharmacother,2005,6(2):319-328.
  • 5伦立德.肾性骨病的治疗措施[J].中国血液净化,2004,3(4):178-180. 被引量:15
  • 6郑法雷,袁群生.肾性骨病诊治中的新问题及有关进展[J].实用医院临床杂志,2006,3(4):2-5. 被引量:18
  • 7Ishida M,Yao N,Yachiku S,et al.Management of calcium,phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride andvitamin D therapy.Ther Apher Dial,2005,9 Suppl:S16-21.
  • 8<活性维生素D的合理应用>专家协作组.活性维生素D在慢性肾脏病继发性甲旁亢中合理应用的专家共识(修订版)[J].中华肾脏病杂志,2005,21(11):698-699. 被引量:97

二级参考文献29

  • 1[1]Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis,1998, 31:607-617
  • 2[2]Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis, 2000, 35:1226-1237
  • 3[3]Wingen AM, Fabian-Bach C, Schaefer F, et al. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet, 1997, 349:1117-1123
  • 4[4]Delmez JA, Kelber J, Norword KY, et al. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int, 1996, 49:163-167
  • 5[5]Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride](RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure]. Am J Kidney Dis,1997, 29:66-71
  • 6[6]Foley RN, Parfrey PS, Harnett JD, et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol, 1996, 16:386-393
  • 7[7]Nordal KP, Dahl E, Halse J, et al. Long-term low-dose calcitriol treatment in predialysis chronic renal failure: Can it prevent hyperparathyroid bone disease? Nephrol Dial Transplant, 1995, 10:203-206
  • 8[8]Herrmann P, Ritz E, Schmidt-Gayk H, et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial, Nephron,1994, 67(1):48-53
  • 9[9]Liou HH, Chiang SS, Huang TP, et al. Akmal M: Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab, 1994, 20:97-102
  • 10[10]Fabretti F, Calabrese V, Fornasari V, et al. Subtotal parathyroidectomy for secondary hyperparathyroidism in chronic renal failure. J Laryngol Otol,1991, 105:562-567

共引文献122

同被引文献251

引证文献27

二级引证文献178

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部